Though no validated biomarker has been identified for antiangiogenic drugs, study on NSCLC indicated that genetic alternations of ARID1A, BRCA2 and IDHexon4 could potentially be used to guide anlotinib therapy.27 This evidence concerns the gene ARID1A and non-small cell lung carcinoma.